MedTrace Logo

Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

NCT06178679 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2024-01-18

No results posted yet for this study

Summary

A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease (DED)

Conditions

Interventions

DRUG

ST-100 (vezocolmitide)

ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml

DRUG

Vehicle

Vehicle Ophthalmic Solution

Sponsors & Collaborators

  • Stuart Therapeutics, Inc.

    collaborator INDUSTRY

  • ORA, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-29
Primary Completion
2024-06-30
Completion
2024-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06178679 on ClinicalTrials.gov